Pure Global

A Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects - Trial NCT06379867

Access comprehensive clinical trial information for NCT06379867 through Pure Global AI's free database. This Phase 1 trial is sponsored by Haisco Pharmaceutical Group Co., Ltd. and is currently Recruiting. The study focuses on Anesthesia. Target enrollment is 48 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06379867
Phase 1
Recruiting
drug
Trial Details
ClinicalTrials.gov โ€ข NCT06379867
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects
A Randomized, Positive and Placebo-Controlled Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects

Study Focus

Anesthesia

HSK3486

Interventional

drug

Sponsor & Location

Haisco Pharmaceutical Group Co., Ltd.

Beijing, China

Timeline & Enrollment

Phase 1

Apr 07, 2024

Aug 30, 2024

48 participants

Primary Outcome

ฮ”QTcI

Summary

Assess the effects of a single IV bolus of HSK3486 single dose on cardiac repolarization for
 healthy subjects.

ICD-10 Classifications

Anaesthetic, unspecified
Other and unspecified general anaesthetics
Local anaesthetics
Other complications of anaesthesia
Complication of anaesthesia during labour and delivery, unspecified

Data Source

ClinicalTrials.gov

NCT06379867

Non-Device Trial